NCCN and ESMO recommend, at minimum, testing for fusions in FGFR2 and NTRK, mutations in IDH1 and BRAF, over-expression or amplifications of HER2/ERBB2, tumor-mutational burden (TMB), and microsatellite instability (MSI). Here, FGFR2 is linked to neoplasm.